 Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 | | 1996 | 0 | 2 | 2 | | 1997 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 4 | 4 | | 2005 | 3 | 3 | 6 | | 2006 | 6 | 7 | 13 | | 2007 | 11 | 4 | 15 | | 2008 | 7 | 10 | 17 | | 2009 | 5 | 6 | 11 | | 2010 | 19 | 11 | 30 | | 2011 | 11 | 9 | 20 | | 2012 | 17 | 10 | 27 | | 2013 | 22 | 14 | 36 | | 2014 | 23 | 15 | 38 | | 2015 | 23 | 12 | 35 | | 2016 | 18 | 18 | 36 | | 2017 | 16 | 10 | 26 | | 2018 | 30 | 19 | 49 | | 2019 | 26 | 19 | 45 | | 2020 | 10 | 10 | 20 | | 2021 | 11 | 14 | 25 | | 2022 | 7 | 27 | 34 | | 2023 | 0 | 23 | 23 | | 2024 | 6 | 19 | 25 | | 2025 | 12 | 6 | 18 |
To return to the timeline, click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Strong Caldwell A, Milner DC, Mehta NB, Marin AI, Gill ZS, Manoharan N. MERTK INHIBITOR-ASSOCIATED RETINAL TOXICITY IN A HUMAN. Retin Cases Brief Rep. 2025 Nov 01; 19(6):807-810.
-
Baird RD, Bermejo de Las Heras B, Ruiz-Borrego M, Vaklavas C, Moreno I, Oliveira M, Armstrong A, Turner N, Incorvati J, Twelves C, Ciruelos E, Hamilton E, Patel MR, Kabos P, Ciardullo C, Klinowska T, Lindemann JPO, Mathewson AM, Morrow CJ, Sykes A, Yang J, Zhang B, Victoria I. Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1. Clin Cancer Res. 2025 Oct 15; 31(20):4244-4254.
-
Nguyen VT, Chandler C, Strang JE, Astridge DD, Reigan P. RiSKs in Computational Modeling of Isoform-Selective RSK Inhibitors. J Chem Inf Model. 2025 Aug 25; 65(16):8411-8425.
-
Tiago M, Purwin TJ, Stefanski CD, da Silva RO, Fane ME, Chhabra Y, Haj JI, Teh JL, Kadamb R, Cai W, Rosenbaum SR, Chua V, Hacohen N, Davies MA, Villanueva J, Chervoneva I, Weeraratna AT, Erkes DA, Capparelli C, Aguirre-Ghiso JA, Aplin AE. Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma. J Clin Invest. 2025 Sep 16; 135(18).
-
Pearson AD, Chi S, Laetscht TW, Marshall L, Raetz E, George RE, Chesler L, Karres D, Scobie N, Knoderer H, Weigel B, Teachey D, Sonke GS, Seibel N, Pappo A, Nysom K, Muscal J, Molenaar J, McDonough J, Macy ME, Ludwinski D, Lin C, Ligas F, Lesa G, Knox L, Kirschbaum M, Kieran M, Kholmanskikh O, Jacobson A, Heenen D, Hawkins DS, Glade Bender J, Fox E, Demolis P, de Rojas T, Cox MC, Chauvin B, Blanc P, Vassal G. Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration. Eur J Cancer. 2025 Aug 26; 226:115629.
-
Xing YL, Panovska D, Park JW, Grossauer S, Koeck K, Bui B, Nasajpour E, Nirschl JJ, Feng ZP, Cheung P, Habib P, Wei R, Wang J, Thomason W, Monje M, Xiu J, Beck A, Weber KJ, Harter PN, Lim M, Mahaney KB, Prolo LM, Grant GA, Ji X, Walsh KM, Mulcahy Levy JM, Hambardzumyan D, Petritsch CK. BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAFV600E-mutant glioma. Cell Rep Med. 2025 Jun 17; 6(6):102183.
-
Shagisultanova E, Parris H, Liu L, Giangiuli S, Gao D, Diamond JR, Acharya-Leon R, Kabos P, Borges VF. Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer. Clin Breast Cancer. 2025 Oct; 25(7):643-649.e1.
-
Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov; 26(7):e503-e513.e11.
-
Xu Y, Yang JC, Zhao Y, Doucet L, Zhou J, Wang Y, Planchard D, Fan Y, Jin B, Han Z, Greillier L, Mazieres J, Sun M, Hu Y, Song X, Ding C, Wu L, Tang K, Liang L, Yao Y, Cheng Y, He Y, Ferreira BP, Ghiringhelli F, Felip E, Bosch-Barrera J, Liu A, Yu Y, Dong X, Gao J, Camidge DR, Nian W, Zhou C, Yang R, John T, Gao B, Bazhenova L, Nagasaka M, Wang J, Ren X, Xu F, Li W, Zhao D, Wang H, Sun S, Huang J, Zhu X, Zheng L, Jänne PA, Wang M. Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation. Cell Rep Med. 2025 May 20; 6(5):102121.
-
Barsouk A, Elghawy O, Watts A, Reed-Guy L, Tompkins W, Chandrasekhara K, Grady CB, Iams W, Sun F, Liu G, Patel D, Nieva JJ, Marrone KA, Velcheti V, Liu SV, Patil T, Weiss J, Schwartzman W, Villaruz LC, Hermann A, Aisner DL, Hwang WT, Camidge DR, Sun L, Singh AP, Cohen RB, Aggarwal C, Langer CJ, Marmarelis ME. Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis. Lung Cancer. 2025 May; 203:108551.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|